SCHEMBL4105481

SCHEMBL4105481

CN(C)C(=O)C=Cc1ccccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
GSR P00390 1/20 0.57
MAPT P10636 9/20 0.55
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 2/20 0.55
ALDH1A1 P00352 2/20 0.55
TP53 P04637 2/20 0.55
MAOB P27338 3/20 0.53
HSP90AA1 P07900 1/20 0.53
LMNA P02545 4/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 2/20 0.51
THRB P10828 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP1A1 P04798 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5680290 0.86 MAOB (0.57) HDAC1HDAC8HDAC6GSRMAPT
SCHEMBL5680288 0.86 MAOB (0.57) HDAC1HDAC8HDAC6GSRMAPT
SCHEMBL11697161 0.85 HDAC1 (0.53) HDAC1HDAC8HDAC6GSRMAPT
SCHEMBL11697165 0.85 HDAC1 (0.53) HDAC1HDAC8HDAC6GSRMAPT
SCHEMBL15128556 0.81 HDAC1 (0.49) HDAC1HDAC8HDAC6GSRMAPT
SCHEMBL19954281 0.80 TRPM8 (0.48) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL6603607 0.80 MAPT (0.54) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL3732406 0.80 TRPM8 (0.48) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1447672 0.79 MAPT (0.63) HDAC1HDAC8HDAC6GSRMAPT
SCHEMBL31356685 0.79 MAPT (0.63) HDAC1HDAC8HDAC6GSRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111018735-B Preparation method of cinnamamide compound 河南农业大学 2021-09-07 CN disclosed
CN-111018735-A Preparation method of cinnamamide 河南农业大学 2020-04-17 CN disclosed
US-8962834-B2 Modulators of amyloid beta HOFFMANN-LA ROCHE INC. (US) 2015-02-24 US disclosed
EP-2257541-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2013-08-14 EP disclosed
US-20130190302-A1 MODULATORS OF AMYLOID BETA HOFFMANN-LA ROCHE INC. (US) 2013-07-25 US disclosed
US-20090215759-A1 MODULATORS FOR AMYLOID BETA HOFFMANN-LA ROCHE, INC. 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215759-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, APOB HDAC1 2405/4885HDAC8 3205/4885HDAC6 2964/4885
US-20130190302-A1 MODULATORS OF AMYLOID BETA APP, PSEN1, APOB HDAC1 2398/4885HDAC8 3349/4885HDAC6 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.